Related Experiment Video

Updated: Feb 28, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.8K

Intravenous Ferumoxytol in Pediatric Patients With Iron Deficiency Anemia

Nabil Hassan1, Brian Boville2, Diann Reischmann3

  • 11 Children's Hospital of Illinois at OSF St Frances, Peoria, IL, USA.

The Annals of Pharmacotherapy
|June 18, 2017
PubMed

Insights

Ferumoxytol effectively treats iron deficiency anemia in children, showing significant improvements in hemoglobin and ferritin levels. Adverse drug reactions were infrequent and manageable with slow infusion and monitoring.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Anemia Management

Background:

  • Iron deficiency anemia (IDA) is a prevalent condition in pediatric populations.
  • Limited data exist regarding the efficacy and safety of ferumoxytol in children.

Purpose of the Study:

  • To evaluate the effectiveness of a 10 mg/kg ferumoxytol dose administered over 15-60 minutes for correcting IDA in children.
  • To document any adverse drug reactions (ADRs) associated with ferumoxytol treatment.

Main Methods:

  • A retrospective review of pediatric patients treated with ferumoxytol for IDA between October 2010 and March 2015.
  • Analysis of pre- and post-infusion hemoglobin and serum ferritin levels.
  • Documentation of all reported adverse drug reactions.

Main Results:

  • Ferumoxytol treatment led to a significant increase in hemoglobin and serum ferritin levels at 1 and 4 weeks post-infusion.
  • Concomitant erythropoietin use was associated with a greater hemoglobin rise at 4 weeks.
  • Infrequent ADRs included pruritus, urticaria, and multisymptom episodes, all responsive to treatment.

Conclusions:

  • Ferumoxytol demonstrates efficacy in treating pediatric iron deficiency anemia.
  • Slow infusion rates and close patient monitoring facilitate early detection of rare adverse events.
Abstract

Keywords:
erythropoietinferumoxytolinflammatory bowel diseaseintravenous ironiron deficiency anemiamalabsorptionpediatric anemiashort gut

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.5K
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
434
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
77
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
338